

The **A**trial **F**ibrillation **A**nd **S**troke
Thromboprophylaxis in h**E**art failu**R**e

(AFASTER) Study.

Patient-centered approaches to thromboprophylaxis in
heart failure with atrial fibrillation.

Caleb Ferguson RN, BScN, MHIth

This thesis is presented in fulfilment of the Degree of

Doctor of Philosophy

University of Technology Sydney.

December 2014

CERTIFICATE OF ORIGINAL AUTHORSHIP

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Student:

Name: Caleb Ferguson

Date: 19th December 2014.

ACKNOWLEDGEMENTS

Words cannot express the gratitude I owe to my dear friends and colleagues. This thesis represents a phenomenal life transition and enormous professional growth. A PhD is a journey, one filled with discovery and reflection. Support from my peers along this journey has made it what it is.

I will never forget the day visiting Trish, Michelle and Phil at Curtin University on Regent Street, after Dean John Daly suggested I should meet Trish and her team. A friendly lady greeted me, with fine bone china tea cups. Little did I know how much this moment would shape my life. Trish, you are a legend. I thank you for your guidance and mentorship. I am forever grateful for your confidence in me. You are a visionary leader.

I would like to express my thanks to my supervisors Dr. Sally Inglis & Dr. Phil Newton, and Professor Peter Macdonald for the practical supervision during my candidacy. I am forever indebted. To my peers and colleagues in the Centre and the Faculty I thank for your support. There are far too many to name! I would also like to express special appreciation to Christine Hwang for support during participant screening, Ros Prichard for coffee and deep thought, and Dr. Michelle DiGiacomo for home baked goods.

To the staff, patients and their caregivers at St Vincent's Hospital, thank you for allowing me to be part of the team, and for insight into living with chronic heart failure and atrial fibrillation. To my colleagues at the ACU NRI, particularly Professor Sandy Middleton for her ongoing support during my candidature, thank you. Thanks to the executive and members of ACNC and CSANZ for permitting me to conduct my survey of cardiovascular nurses. To my sister, Leila, for inspiration and encouragement. Last but not least, to my partner Pete, for your love and support.

FUNDING SOURCES

The following funding sources are thankfully acknowledged:

- Small Project Grant, Australian College of Nursing.
- John Sheard Award, Australasian Neuroscience Nurses Asc. NSW Chapter.
- Heart Failure Council Travel Fellowship, CSANZ.
- Doctoral Scholarship, University of Technology, Sydney.

ANTHOLOGY OF PUBLICATION AND PRESENTATIONS ASSOCIATED WITH THIS THESIS

PEER REVIEWED PUBLICATIONS RELATED TO THIS THESIS

1. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2013) Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. *Vascular Health and Risk Management*. Vol.9 Pp3-11.
2. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Atrial fibrillation: stroke prevention in focus. *Australian Critical Care*. Vol. 27 No. 2 Pp 92-98. **(Impact factor 1.265)**.
3. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) The role of the caregiver in thromboprophylaxis management in atrial fibrillation (2014) *European Journal of Cardiovascular Nursing* (E-Pub Ahead of Print). **(Impact factor 2.042)**.
4. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Education and practice gaps on atrial fibrillation and anticoagulation: A survey of cardiovascular nurses. *BMC Medical Education* (SUBMITTED: IN REVIEW) **(Impact factor 1.50)**.
5. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Barriers and enablers to anticoagulation in heart failure with atrial fibrillation: patient, provider and health system perspectives. *Drugs and Aging* (SUBMITTED: IN REVIEW) **(Impact factor: 2.503)**.
6. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Multimorbidity, frailty and self-care: Important considerations in anticoagulant decision making in heart failure with atrial fibrillation. *Journal of Cardiac Failure* (SUBMITTED: IN REVIEW) **(Impact factor: 3.065)**.
7. **Ferguson C** & Davidson PM. (2014) The importance of communicating your research: The 3 Minute Thesis. *Advances in Nursing Doctoral Education & Research (ANDER)*: Official Journal for the International Network for Doctoral Education in Nursing (INDEN). Vol. 2. Vo.1 Pp11 -14.

CONFERENCE PRESENTATIONS RELATED TO THIS THESIS

1. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) The caregiver role in thromboprophylaxis management in atrial fibrillation. Nursing Research Institute Symposium, St Vincent's Hospital, Sydney, Nov 2014.
2. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) The caregiver role in thromboprophylaxis management in atrial fibrillation. Australasian Cardiovascular Nursing College 8th Annual Scientific Meeting, Gold Coast, Australia, Feb 2014 (*Awarded Best Oral Presentation*).
3. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) The Atrial Fibrillation And Stroke Thromboprophylaxis in hEart failure (AFASTER) cohort study: 90 day outcomes. European Society of Cardiology: Heart Failure Congress, Athens, Greece, May 2014 in European Journal of Heart Failure Supplements, P282. (**Impact factor: 6.577**)
4. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Frailty and thromboprophylaxis prescription in heart failure and atrial fibrillation: Preliminary findings from the Atrial Fibrillation And Stroke Thromboprophylaxis in hEart failure (AFASTER) cohort study'. World Congress of Cardiology, Melbourne, Australia, May 2014, in Global Heart Journal. E264 (**Impact factor: 0.612**)
5. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2014) Thromboprophylaxis prescription in hospitalised patients with heart failure and concomitant atrial fibrillation: Preliminary findings from the Atrial Fibrillation And Stroke Thromboprophylaxis in hEart failure (AFASTER) cohort study' World Congress of Cardiology, Melbourne, Australia, May 2014, in Global Heart Journal. E109 (**Impact factor: 0.612**)
6. **Ferguson C**, Inglis SC, Newton PJ, Middleton S, Macdonald PS & Davidson PM (2013) Stroke prevention in heart failure: time to rethink risk predication schemes? World Federation of Neuroscience Nurses Congress, Gifu, Japan. October 2013.
7. **Ferguson C**, Inglis SC, Newton PJ, Middleton S & Davidson PM (2012) Atrial fibrillation and thromboprophylaxis: methods in risk assessment and addressing barriers to adherence: A review. Australasian Cardiovascular Nursing College. Coogee, Sydney, Feb 2012.

OTHER PUBLISHED WORKS RELATED TO THIS THESIS

1. Davidson PM & **Ferguson C** (2013) Chapter 25, "Management of Patients with Complications for Heart Disease" in *Farrell & Dempsey: Smeltzer & Bare's Textbook of Medical Surgical Nursing*. 3rd Edition. ISBN 9781 9209 94648 [PUBLISHED SEPT 2013] pp686-710
2. **Ferguson C** (2013) "Unhealthy Buzz" *U:Magazine*, June Edition. Available via <http://newsroom.uts.edu.au/umag>
3. **Ferguson C** & Davidson (2012) "Energy drink binge leaves teens with more than a hangover" *The Conversation*. April 2012. Available via: <https://theconversation.edu.au/energy-drink-binge-leaves-teens-with-more-than-a-hangover-6165>
4. **Ferguson C** & Davidson PM (2012) "Getting to the heart of the matter on stroke" *The Conversation*. May 2012 Available via: <https://theconversation.edu.au/getting-to-the-heart-of-the-matter-on-stroke-7180>
5. **Ferguson C**, DiGiacomo M, & Davidson PM (2012) "Lady Killer: the hidden dangers to women's health. *The Conversation*. July 2012. Available via: <https://theconversation.edu.au/ladykiller-the-hidden-danger-to-womens-health-7591>

AWARDS AND PRIZES RELATED TO THIS THESIS

- 2014 CSANZ Travel Fellowship
- 2014 UTS Vice Chancellor's Post Graduate Travel Award
- 2014 Australian Cardiovascular Nursing College – Best Oral Presentation.
- 2014 Australian Cardiovascular Nursing College Travel Scholarship
- 2013 John Sheard Travel Award
- 2013 UTS: HSP Funding Research Development Award
- 2012 Australian College of Nursing. Scholarship Grant
- 2012 John Sheard Travel Award
- 2012 UTS 3 Minute Thesis – Faculty of Health – University Finalist

TABLE OF CONTENTS

Acknowledgements.....	ii
Funding Sources.....	iii
Anthology of publication and presentations associated with this thesis	iv
Peer reviewed publications related to this thesis	iv
Conference presentations related to this thesis	v
Other published works related to this thesis	vi
Awards and prizes related to this thesis.....	vii
List of tables.....	xiv
List of figures.....	xvi
List of appendices	xvii
List of acronyms and abbreviations used in this thesis	xviii
Thesis Abstract.....	xxii
1. Chapter 1: Introduction.....	1
1.1. Background.....	1
1.2. Chronic heart failure	2
1.2.1. Definition of chronic heart failure.....	2
1.2.2. Heart failure severity classifications	3
1.3. Atrial fibrillation	5
1.3.1. Definition of atrial fibrillation.....	5
1.3.2. Incidence and prevalence	6
1.4. AF and CHF comorbidity in clinical trials.....	8
1.5. Evidence-based practice and knowledge translation.....	9
1.6. Patient-centered care.....	9
1.6.1. Shared Decision Making	10
1.6.2. Adherence	11
1.6.3. Multimorbidity	12
1.6.4. Frailty.....	13
1.7. Heart Failure Self Care Behaviour.....	14
1.8. Contrast between risk stratification and a patient centered assessment	15
1.9. Significance and Innovation.....	16
1.10. Study Objectives	17
1.10.1. Study Aims.....	17
1.10.2. Research Questions.....	18

1.11.	Outline of this thesis	19
1.12.	Structure of this thesis.....	23
1.13.	References.....	24
2.	Chapter 2: Atrial fibrillation: Stroke prevention in focus	30
2.1.	Chapter preface	30
2.2.	Introduction.....	33
2.3.	Aims & Objectives.....	33
2.4.	Methods.....	34
2.5.	Atrial fibrillation	34
2.5.1.	Definition and classification	36
2.5.2.	Screening and diagnosis.....	38
2.6.	Epidemiology of Atrial Fibrillation and Stroke in Australia.....	39
2.7.	Stroke Prevention.....	39
2.8.	Hospitalisations.....	40
2.9.	Stroke and bleeding risk assessment tools	40
2.10.	Treatment and management of atrial fibrillation	41
2.10.1.	Pharmacological interventions to prevent stroke in AF	45
2.10.2.	Non Pharmacological interventions to treat AF.....	48
2.11.	Lifestyle advice and patient education.....	49
2.12.	Future research.....	50
2.13.	Conclusion	50
2.14.	References.....	51
3.	Chapter 3: Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence.....	57
3.1.	Chapter preface	57
3.2.	Introduction.....	59
3.3.	Stroke and bleeding risk assessment schemata in AF	60
3.4.	Adherence	64
3.5.	Health system-related factors.....	65
3.6.	Solution to health system-related factors	66
3.7.	Treatment-related factors	66
3.8.	Solutions to treatment-related factors	67
3.9.	Socioeconomic-related factors.....	68
3.10.	Solutions to socioeconomic-related factors	68
3.11.	Patient-related factors	69
3.12.	Solutions to patient-related barriers	69

3.13.	Condition-related factors.....	70
3.14.	Solutions to condition-related factors	71
3.15.	Implications for clinical practice.....	74
3.16.	Conclusion	75
3.17.	References.....	76
4.	Chapter 4: The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review.	83
4.1.	Chapter preface	83
4.2.	Background	86
4.2.1.	Who is a caregiver?.....	86
4.3.	Objectives	89
4.4.	Methods.....	90
4.5.	Results.....	91
4.6.	Discussion.....	94
4.6.1.	Models of AF management.....	95
4.6.2.	Caregiver education	96
4.6.3.	Medication management	97
4.6.4.	Advocacy and shared decision-making.....	98
4.6.5.	Support from health care.....	99
4.6.6.	Caregiver burden.....	100
4.7.	Limitations	101
4.8.	Underrepresentation in research.....	101
4.9.	Implications for Clinical Practice and Research	102
4.10.	Conclusion	103
4.11.	References.....	104
5.	Chapter 5: Barriers and enablers to anticoagulation in heart failure with atrial fibrillation: patient, provider & health system perspectives.	109
5.1.	Chapter preface	109
5.2.	Background	112
5.3.	Aims & Objectives.....	113
5.4.	Method	113
5.4.1.	Data sources, design and setting	113
5.4.2.	Participants.....	114
5.4.3.	Ethical Considerations	114
5.4.4.	Interview schedule	115
5.5.	Data analysis	115

5.6.	Results.....	116
5.6.1.	Demographic and clinical characteristics.....	116
5.6.2.	Treatment-related factors.....	118
5.6.3.	Socio-economic factors.....	119
5.6.4.	Condition-related factors.....	119
5.6.5.	Health-system related factors.....	121
5.6.6.	Patient-related factors.....	123
5.7.	Discussion.....	127
5.8.	Patient preference, choice and shared decision-making.....	128
5.9.	Limitations.....	128
5.10.	Conclusion.....	129
5.11.	References.....	130
6.	Chapter 6: Education and practice gaps on atrial fibrillation and anticoagulation: A survey of cardiovascular nurses.....	134
6.1.	Chapter preface.....	134
6.2.	Introduction.....	137
6.3.	Study Aim.....	138
6.4.	Methods.....	139
6.4.1.	Design, setting and sample.....	139
6.4.2.	Measurements and item generation.....	139
6.4.3.	Data collection.....	140
6.4.4.	Data management and data analysis.....	140
6.4.5.	Ethical considerations.....	140
6.5.	Results.....	141
6.5.1.	Sample characteristics, demographic information and experience.....	141
6.5.2.	Adverse outcomes.....	144
6.5.3.	Nurses role in decision making and anticoagulation.....	145
6.5.4.	Barriers to anticoagulation.....	147
6.5.5.	Practice patterns.....	149
6.5.6.	Cardiovascular nurses' knowledge on warfarin interactions.....	151
6.5.7.	Cardiovascular nurses' knowledge on warfarin related advice.....	153
6.6.	Discussion.....	156
6.6.1.	Practice patterns.....	156
6.6.2.	Knowledge.....	157
6.7.	Limitations.....	158
6.8.	Conclusion and implications.....	159

6.9.	References.....	161
7.	Chapter 7: Multimorbidity, frailty and self-care: Important considerations in anticoagulation.....	163
7.1.	Chapter preface	163
7.2.	Introduction.....	166
7.3.	Purpose.....	166
7.4.	Methods.....	167
7.4.1.	Design and setting.....	167
7.4.2.	Measurements	167
7.4.3.	Data management, statistical analyses	170
7.4.4.	Ethical considerations	171
7.5.	Results.....	171
7.5.1.	Sample baseline characteristics and demographic information	171
7.5.2.	12 month outcomes	178
7.6.	Discussion.....	181
7.6.1.	Importance of considering multimorbidity	182
7.6.2.	Guideline based therapy in the context of multimorbidity.....	183
7.6.3.	High risk of rehospitalisation and death.....	184
7.6.4.	Living alone and frailty as risk factors for increased hospitalization and mortality 185	
7.7.	Limitations	186
7.8.	Conclusion and implications.....	187
7.9.	References.....	188
8.	Chapter 8: Conclusion: Implications for practice, policy and research.	192
8.1.	Review and Discussion	192
8.2.	AF clinical practice guidelines.....	193
8.3.	Clinical assessment and decision making for thromboprophylaxis	194
8.4.	Shared decision making to promote adherence.....	196
8.5.	Increasing attention to the caregiver	198
8.6.	Evolving models of AF care	200
8.7.	Improving patient education and self-management	203
8.8.	Redefining AF nurse education.....	207
8.9.	Better understanding choice, preferences, and attitudes	209
8.10.	Eight key recommendations generated from this thesis.....	211
8.11.	Conclusions.....	212
8.12.	References.....	213

9 Appendices..... 217

LIST OF TABLES

Table 1.1 Heart failure survival rates from Framingham data	2
Table 1.2 NYHA functional classification system.....	3
Table 1.3 ACC/ AHA Classification of heart failure.....	3
Table 1.4 Classification of AF	5
Table 1.5 Prevalence of frailty in heart failure.	13
Table 2.1 Cardiac and non-cardiac risk factors for the development of AF	35
Table 2.2 General signs and symptoms of AF	38
Table 2.3 Stroke risk stratification schemata	42
Table 2.4 The HAS-BLED Score	43
Table 2.5 Recommended pharmacological agents for stroke prevention in AF	44
Table 3.1 Stroke risk stratification with CHADS2 and CHA2DS2-VASc assessment tools	62
Table 3.2 The HAS-BLED score	63
Table 3.3 Barriers to thromboprophylaxis	64
Table 4.1 Summary of studies	92
Table 5.1 Key barriers from the perspective of the patient, provider & health system	117
Table 6.1 Characteristics of cardiovascular nurses.....	142
Table 6.2 Previous participation in educational programs.....	143
Table 6.3 Clinical factors.....	144
Table 6.4 Clinical decision making in anticoagulation.....	146
Table 6.5 Barriers to anticoagulation.....	147
Table 6.6 Factors facilitating optimal management of thromboprophylaxis	148
Table 6.7 Nurses general comments about thromboprophylaxis.....	148
Table 6.8 Cardiovascular nurses practice patterns.....	150
Table 6.9 Cardiovascular nurses knowledge on warfarin drug interactions.	152
Table 6.10 Cardiovascular nurses knowledge on how to advise patients on warfarin.....	154
Table 7.1 Baseline demographics and clinical characteristics.....	174

Table 7.2 Unadjusted events at 12 months post-hospitalization.178

Table 7.3 Mean event free time composite endpoint of all-cause hospitalization and mortality
.....179

LIST OF FIGURES

Figure 1.1 AF and HF both as causes and effects of the AF-HF complex: a vicious cycle and bidirectional model.	7
Figure 1.2 Prevalence of AF in CHF Clinical Trials	8
Figure 1.3 Prevalence of CHF in AF Clinical Trials	8
Figure 1.4 Structure of this thesis	23
Figure 2.1 Patterns of AF.....	37
Figure 4.1 Prisma Flow Diagram.....	91
Figure 6.1 Final sampling frame response.....	141
Figure 7.1 Participant recruitment and screening	172
Figure 7.2 Stroke risk distribution per anticoagulation status at discharge.	175
Figure 7.3 Bleeding risk distribution per anticoagulation status at discharge.	176
Figure 7.4 Discharge pharmacotherapy categorised by discharge by coagulation status at discharge.	177
Figure 7.5 Kaplan-meier survival analysis for composite endpoint of all-cause hospitalisation and mortality.	179
Figure 7.6 Kaplan-meier survival analysis for composite endpoint of all-cause mortality.	180

LIST OF APPENDICES

Appendix 1: HREC approval	217
Appendix 2: Amendment to survey distribution.....	219
Appendix 3: Amendment to method of consent	220
Appendix 4: Site specific authorisation	221
Appendix 5: Participant consent form	222
Appendix 6: Participant screening tool.....	234
Appendix 7: Case report form.....	235
Appendix 8: Atrial fibrillation: stroke prevention in focus.....	242
Appendix 9: Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence.....	247
Appendix 10: The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review	256
Appendix 11: Permissions to reproduce published works	266

LIST OF ACRONYMS AND ABBREVIATIONS USED IN THIS THESIS

ACC: American College of Cardiology

ACNC: Australian Cardiovascular Nursing College

AF: Atrial Fibrillation

AFASTER: The Atrial Fibrillation And Stroke Thromboprophylaxis in hEart failure Study

AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management trial

AHA: American Heart Association

ANZ: Australia and New Zealand

ARITOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

ATRIA: The AnTicoagulation and Risk Factors in Atrial Fibrillation Study

AVERROES: Apixaban versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment trial.

BAFTA: The Birmingham Atrial Fibrillation Treatment of the Aged Trial

CCI: Charlson Comorbidity Index

CCU: Coronary Care Unit

CHA₂DS₂VASc: (Congestive heart failure, Hypertension, Age \geq 75 years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism)

CHADS₂: (Congestive heart failure or left ventricular systolic dysfunction, Hypertension, Age \geq 75 years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism, Vascular disease, Age 65-74, Sex category i.e. female sex)

CHARM: Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Study

CHF STAT: The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy trial

CHF: Chronic Heart Failure

CIBIS II: The Cardiac Insufficiency Bisoprolol Study II

CINAHL: Cumulative Index to Nursing and Allied Health Literature

COMET: Carvidilol Or Metoprolol European Trial

CONSENSUS: The Cooperative North Scandinavia Enalapril Survival Study

CPG: Clinical Practice Guideline

CrCl: Creatinine Clearance

CSANZ: Cardiac Society of Australia and New Zealand

DBP: Diastolic Blood Pressure

DCE: Discrete Choice Experiment

DIAMOND CHF: Danish Investigations of Arrhythmia and Mortality ON Dofetilide Study

DIG: The Digitalis Investigation Group Trial

ECG: Electro Cardio Graph

eGFR: Estimated Glomerular Filtration Rate

EHFScBS: European Heart Failure Self-care Behaviour Scale

ENGAGE: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation – Thrombolysis in Myocardial Infarction 48 trial

GESICA: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina Study

GP: General Practitioner/ Primary care physician

HAS-BLED: (Hypertension, Abnormal renal/ liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drug/ alcohol concomitantly).

HEMMORR₂HAGES: (Hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet count, re-bleeding risk, anemia, genetic factors, excessive falls risk, stroke)

HF: Heart Failure

HRS: Heart Rhythm Society

INR: International Normalized Ratio

LAA: Left Atrial Appendage

LVEF: Left Ventricular Ejection Fraction

MERIT HF: Metoprolol CR/XL Randomized Intervention Trial in-Congestive Heart Failure

MMSE: Mini Mental State Examination

MOCA: Montreal Cognitive Assessment

MORISKY: 4 item medication adherence self-report questionnaire

NOAC: Novel Oral Anticoagulant

NSW: New South Wales

NT-Pro-BNP: N-terminal prohormone of brain natriuretic peptide

NYHA: New York Heart Association Classification

OPTIMAAL: Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan trial

OPTIME CHF: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure Study.

PBS: Pharmaceutical Benefits Scheme

PCC: Patient Centered Care

PRIME: The Prospective Epidemiological Study of Myocardial Infarction Study

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PSM: Patient Self-Monitoring/ Patient Self-Management

PST: Patient Self-Testing

RE-LY: The Randomized Evaluation of Long-Term Anticoagulation Therapy trial

ROCKET AF: Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial.

SAFETY: Standard versus atrial fibrillation-specific management strategy to reduce recurrent admission and prolong survival: pragmatic, multicenter randomized controlled trial.

SBP: Systolic Blood Pressure

SDM: Shared Decision Making

SHARE-FI: Survey of Health, Ageing and Retirement in Europe Frailty Instrument

SOLVD: Studies of Left Ventricular Dysfunction Prevention Study

SPAF: Stroke Prevention in Atrial Fibrillation

SPORTIF: Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation Study

TGA: Therapeutic Goods Administration

TIA: Transient Ischaemic Attack

TTR: Time in Therapeutic Range

V-HeFT I and II: The Vasodilator Heart Failure Trial

VKA: Vitamin K Antagonist

WARCEF: The Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm Study

WATCHMAN: A nickel-titanium umbrella implantable device

WHO: World Health Organisation

THESIS ABSTRACT

Background

Atrial fibrillation (AF) is a common arrhythmia in heart failure (HF) and presents a significant risk factor for thromboembolic stroke. Despite recommendations in best practice guidelines, implementation of risk stratification, therapeutic approaches for AF and thromboprophylaxis are not uniformly applied in practice.

Purpose

This study aims to identify both barriers and enablers to thromboprophylaxis in patients with HF and AF as a concomitant condition at the levels of the patient, provider and health system.

Methods

This was undertaken through a series of discrete studies, including: (1) a prospective cohort study of individuals with HF and AF at St Vincent's Hospital, Sydney; (2) bedside interviews with patients, and medical file note review; and (3) an electronic survey of cardiovascular nurses to explore their current knowledge and practice patterns.

Results

Patient level: Results of this research demonstrate that patient choice and preference were important factors in thromboprophylaxis decisions, including treatment burden, unfavorable or intolerable side effects and patient refusal. Facilitators to successful prescription and adherence were caregiver support, reminders and routine, self-testing and the use of technology. At a **health system level**, financial barriers included cost of travel; medication cost and reimbursement were important considerations.

Provider level: Survey findings revealed mixed levels of education on AF, stroke risk, anticoagulation and health behavior modification. The CHA₂DS₂VASc and HAS-BLED risk stratification tools were reported to be underused. Nurses reported key barriers to anticoagulation to include; fears of patients falling, fears of poor adherence to medication taking and routine monitoring. Additionally, patient self-monitoring and self-management were reported to be underutilized. Cardiovascular nurses reported their key role to be counselling and advising patients on therapy regimens. Anticoagulant-drug interaction knowledge was generally poor. From the medical file note review, clinician reticence included fear of falls, frailty, age, fear of bleeding and the challenges of multi-morbidity. Psychological factors included psychiatric illness, cognitive impairment and depression. Social barriers included homelessness and the absence of a caregiver or lack of caregiver assistance. The cohort study revealed that 66% of participants were prescribed an anticoagulant at discharge from hospital. Self-reported self-care behavior and ‘not for CPR’ were associated with not receiving anticoagulation at discharge. Whilst statistical significance was not achieved, those who were assessed as frail or having greater comorbidity, were less likely to receive anticoagulation at discharge from hospital.

Recommendations

1. Treatment decisions must be tailored to meet the needs of individuals, whilst balanced in the context of the best available evidence.
2. There is need to formalize the role of the caregiver in the management of AF and CHF.
3. Improved focus on AF within existing chronic care programs is warranted, given the aging population.
4. Developing quality patient education materials and self-management strategies are key priority areas for enhancing sustainable models of care.
5. There is scope for improvement in nurses' knowledge and practice in contemporary AF management.
6. Patient preference, choice and attributes must be considered when making complex thromboprophylaxis treatment decisions.

Conclusion

The findings of this thesis point to the need for patient-centered approaches to the management of AF in the setting of HF, as well as increased skills and competencies for nurses. This thesis demonstrates that although stroke and bleeding risk calculation are important there are other salient considerations in making clinical decisions for thromboprophylaxis including cognitive impairment, multimorbidity, self-care ability and frailty. These factors not only influence decision making on the part of provider and patient but also influence clinical outcomes. Shared decision making provides a framework for patients and providers to have quality communication, negotiate consensus and find agreements on treatment goals. These findings underscore the need for shared decision making when making complex treatment decisions around thromboprophylaxis.